Interstitial cystitis / bladder pain syndrome (IC/BPS) affects an estimated 3–8 million women and 1–4 million men in the United States alone — a condition defined by chronic pelvic pain, urinary urgency, and frequency that can be utterly debilitating. For many patients, years of dietary modification, bladder instillations, oral medications, and even surgical interventions fail to provide lasting relief. MSC therapy is being investigated as a regenerative approach that targets the underlying urothelial defect and neuroinflammatory cycle — not just the symptoms.

IC/BPS is a chronic bladder condition characterized by pelvic pain, pressure, or discomfort perceived to be related to the urinary bladder, accompanied by at least one other urinary symptom such as persistent urge to void or urinary frequency, in the absence of infection or other identifiable pathology.[1]

Where conventional treatments fall short. First-line therapy includes dietary modification, stress management, and pelvic floor physical therapy. When those fail, oral medications — pentosan polysulfate sodium (PPS), amitriptyline, hydroxyzine, cimetidine — are prescribed. Intravesical instillations of heparin, lidocaine, DMSO, or hyaluronic acid aim to replenish the glycosaminoglycan (GAG) layer lining the bladder. In severe cases, bladder hydrodistension, botulinum toxin injection, neuromodulation, or even cystectomy with urinary diversion are considered.[2]

The deeper problem is the urothelial barrier. The bladder urothelium is not a passive lining — it is an active, semi-permeable barrier that regulates solute transport and prevents urinary toxins (potassium, urea) from penetrating the suburothelial nerve plexus. In IC/BPS, the GAG layer is defective, the urothelium becomes leaky, and urinary solutes trigger mast cell degranulation in the submucosa. This releases histamine, tryptase, TNF-α, and nerve growth factor (NGF), which sensitize C-fiber afferents and drive the neuroinflammatory pain cycle.[3]

MSC therapy targets the root cause. Rather than simply blocking mast cell mediators or replacing the GAG layer topically, MSCs offer three complementary mechanisms: (1) direct engraftment and differentiation into urothelial-like cells to repair the barrier, (2) paracrine secretion of anti-inflammatory cytokines (IL-10, TGF-β, TSG-6, PGE2) that suppress mast cell activation and reduce NGF expression, and (3) immunomodulation that shifts the local environment from a pro-inflammatory Th1/Th17 profile toward a regulatory Treg-dominant milieu.[4][5]

Key Point: IC/BPS is increasingly understood as a disorder of the urothelial barrier with secondary neurogenic inflammation. MSCs address both layers — the structural defect and the inflammatory cascade — making them mechanistically distinct from any currently approved IC/BPS therapy.

Pathophysiology of Interstitial Cystitis

IC/BPS is a multifactorial condition with several overlapping pathological mechanisms. The most widely accepted model involves urothelial dysfunction, mast cell activation, neurogenic inflammation, and pelvic floor dysfunction in a self-reinforcing loop.[6]

Urothelial Barrier Dysfunction

In healthy bladders, umbrella cells on the apical urothelial surface express uroplakins and are coated by a GAG layer composed of chondroitin sulfate, heparan sulfate, and hyaluronic acid. This layer prevents urinary solutes from contacting the underlying tissue. In IC/BPS, the GAG layer is thin or absent, tight junction proteins (claudins, occludin, ZO-1) are downregulated, and the urothelium becomes permeable to potassium and urea. Biopsy studies show areas of denuded urothelium — Hunner's lesions in the classic subtype — and a thinned, dysfunctional urothelium in the non-ulcerative subtype.[7]

Mast Cell Activation and Neuroinflammation

Mast cells are found at 6–10 times normal density in the bladder submucosa and detrusor muscle of IC/BPS patients. When urinary solutes penetrate the leaky urothelium, they directly stimulate mast cell degranulation. The released mediators — histamine, tryptase, TNF-α, IL-6, and NGF — have three downstream effects: they further damage the urothelium (positive feedback), they sensitize nociceptive C-fibers producing pelvic pain, and they promote angiogenesis and fibrosis that reduce bladder compliance. Tryptase, in particular, activates protease-activated receptor-2 (PAR-2) on sensory neurons, which is a key driver of visceral hyperalgesia.[8]

Pelvic Floor and Central Sensitization

Chronic bladder pain leads to pelvic floor muscle hypertonicity as a guarding response. This pelvic floor dysfunction then causes myofascial pain and further bladder irritation, completing a vicious cycle. Over time, chronic nociceptive input can induce central sensitization — spinal cord and brain plasticity that amplifies pain signals even after the peripheral trigger is addressed.[9]

How Mesenchymal Stem Cells May Repair the Bladder

MSCs address IC/BPS through a multi-targeted regenerative and immunomodulatory mechanism that distinguishes them from any single-agent pharmacological approach currently available.

Urothelial repair and GAG layer restoration. In rodent models of chemical cystitis, intravenous or intravesical MSC administration leads to homing of cells to the injured bladder, where they engraft into the urothelium and express uroplakin III — a marker of differentiated umbrella cells. Treated bladders show restored GAG layer thickness on electron microscopy, reduced bladder permeability on potassium sensitivity testing, and increased expression of tight junction proteins ZO-1 and occludin. The structural repair is visible within 7–14 days of treatment.[10]

Mast cell suppression. MSC-derived TSG-6 (TNF-α-stimulated gene 6 protein) directly inhibits mast cell degranulation by binding to CD44 on the mast cell surface. Simultaneously, MSC-secreted PGE2 and IL-10 downregulate the IgE receptor (FcεRI) expression on mast cells, reducing their sensitivity to triggers. In rat cystitis models, MSC treatment reduces mast cell counts in the bladder submucosa by 60–75% and lowers urinary histamine and tryptase levels to near-baseline.[11]

Nerve growth factor reduction. NGF is produced by mast cells, urothelial cells, and smooth muscle in the inflamed bladder. It drives sensory nerve sprouting and sensitization. MSCs reduce NGF expression in bladder tissue by 50–70% through paracrine signaling, which correlates with reduced pelvic pain behavior in animal models (decreased visceromotor response to bladder distension).[12]

Immunomodulatory shift. IC/BPS bladder biopsies show elevated levels of pro-inflammatory cytokines — IL-1β, IL-6, IL-8, TNF-α — and a predominance of Th1 and Th17 lymphocytes. MSCs polarize macrophages from an M1 (pro-inflammatory) to an M2 (anti-inflammatory, tissue-repair) phenotype and promote expansion of regulatory T cells (Tregs) that suppress effector T-cell activity in the bladder wall.[13]

Cross-section of bladder wall showing mesenchymal stem cells migrating into damaged urothelium and reducing mast cell infiltration
MSCs migrate to the injured bladder urothelium, where they suppress mast cell degranulation, restore the GAG barrier, and reduce NGF-driven neuroinflammation — a multi-targeted mechanism distinct from any single-drug approach.

Clinical Evidence: What the Studies Show

The clinical evidence for MSC therapy in IC/BPS is early-stage but directionally consistent. No large randomized controlled trial has been completed, but small pilot studies and case series report encouraging signals across multiple endpoints.

Pilot Study Size 10–30 patients All published human studies to date are Phase I or small investigator-initiated trials.
Pain Reduction 40–65% Visual Analog Scale (VAS) pain scores reduced at 3–6 months post-treatment.
Urinary Frequency ↓ 30–50% Daytime and nocturnal voiding frequency decreased in most reported patients.
O'Leary-Sant Score ↓ 40–55% Validated IC symptom and problem index scores improved across studies.

A 2023 pilot study from South Korea enrolled 10 women with Hunner-type IC/BPS refractory to conventional therapy. Patients received a single intravesical instillation of allogeneic umbilical cord-derived MSCs (5 × 10⁷ cells). At 6 months, mean VAS pain scores decreased from 7.8 to 3.2 (p < 0.01), O'Leary-Sant scores improved significantly, and cystoscopic findings showed reduced bladder inflammation. No serious adverse events were reported; transient urinary discomfort was the most common side effect.[14]

An earlier 2021 pilot study from China investigated intravenous infusion of autologous bone marrow-derived MSCs in 15 patients with non-Hunner IC/BPS. At 12 months, 11 of 15 patients reported ≥50% reduction in pain scores, and 9 achieved a significant improvement in quality-of-life measures. The effect appeared to peak around month 6 with gradual attenuation by month 12 in some patients, suggesting that repeat dosing may be needed for durable effect.[15]

Preclinical data from rodent and feline models of cystitis provide a more robust mechanistic picture. Intravenous MSC administration in cyclophosphamide-induced cystitis models reduced bladder edema, hemorrhage, and inflammatory cell infiltration by 60–80% compared to vehicle controls. Treated animals showed normalized micturition patterns, reduced pelvic pain behavior, and — critically — restored urothelial integrity on histology.[16]

Important Caveat: All human MSC studies in IC/BPS are small (n ≤ 30), open-label, and lack sham controls. The placebo response in IC/BPS is substantial — typically 20–40% in pharmaceutical trials. Without randomized sham-controlled data, the true treatment effect size cannot be reliably estimated. Larger controlled trials are essential before MSC therapy can be considered an evidence-based option.

Treatment Protocol at VELAR

VELAR Center's approach to IC/BPS is personalized based on disease subtype, severity, and prior treatment history.

Comprehensive assessment. Every patient undergoes a thorough evaluation including detailed symptom history, validated questionnaires (O'Leary-Sant ICSI/ICPI, VAS pain score, 3-day voiding diary), pelvic examination, urinalysis, and, when indicated, cystoscopy with hydrodistension to classify the disease as Hunner-type or non-Hunner-type. Review of prior treatments — oral medications, bladder instillations, pelvic floor therapy, neuromodulation — guides the treatment plan.

MSC source and dosing. VELAR uses allogeneic umbilical cord-derived MSCs (UC-MSCs) from Wharton's jelly, processed in our ISO 9001-certified GMP laboratory. The rationale for UC-MSCs over bone marrow or adipose sources in IC/BPS is their superior expansion capacity, lower immunogenicity, and higher expression of TSG-6 — the key mast cell-suppressing factor — compared to adult-tissue MSCs. Typical cell doses range from 100 to 200 million MSCs per treatment session.[17]

Delivery route. Two delivery strategies are employed, sometimes in combination: (1) Intravenous infusion for systemic immunomodulation — MSCs home to sites of inflammation including the bladder via chemokine gradients (SDF-1/CXCR4 axis). (2) Intravesical instillation for direct urothelial contact — MSCs are suspended in a hyaluronic acid carrier and instilled into the bladder via catheter with a dwell time of 60–90 minutes, allowing direct adhesion to and integration into the damaged urothelium.

Treatment schedule. A typical initial course involves 2–3 treatment sessions spaced 4–8 weeks apart, with clinical reassessment at each visit. Maintenance sessions may be scheduled every 6–12 months depending on durability of response.

Expected Outcomes and Timeline

Weeks 1–2 Initial Response Reduction in urinary urgency and nocturia; anti-inflammatory effect begins within days of infusion.
Weeks 4–8 Pain Relief Pelvic pain and pressure typically begin to decrease as mast cell activity is modulated and NGF levels fall.
Months 3–6 Urothelial Repair Structural GAG layer restoration and urothelial healing, reflected in sustained improvement in O'Leary-Sant scores.
Months 6–12 Durability Peak effect; maintenance sessions may be indicated depending on individual disease trajectory.

"After eight years of bladder pain and trying every available treatment, MSC therapy gave me the first real window of relief. It didn't cure me — I still manage my diet and stress — but the pain is no longer the center of my life. That is a level of recovery no pharmaceutical ever delivered."

Safety Profile

MSC therapy has a well-characterized safety profile derived from thousands of patients treated across multiple indications. Common transient effects include low-grade fever (12–18%), fatigue (8–15%), and mild infusion-related symptoms (headache, nausea) resolving within 24–48 hours. For intravesical instillation, transient urinary discomfort and mild hematuria may occur for 1–3 days post-procedure.[18]

Serious adverse events are rare. No cases of tumor formation, ectopic tissue growth, or pulmonary embolism have been attributed to UC-MSCs when administered through standard IV or intravesical routes in published studies. VELAR screens all MSC batches for sterility, mycoplasma, endotoxin, and karyotype normalcy before release.

Limitations and Honest Perspective

MSC therapy for IC/BPS is investigational and not yet supported by large-scale clinical evidence. Patients considering this approach should understand the following:

VELAR's Position: We offer MSC therapy for IC/BPS as part of a comprehensive treatment plan for carefully selected patients who have exhausted or declined conventional options. We do not claim cure rates, and we require patients to maintain their established medical care. Every patient receives thorough counseling about the investigational nature of this treatment before proceeding.

Frequently Asked Questions

How much does stem cell therapy for interstitial cystitis cost in Bangkok?

At VELAR Center, a typical treatment course (2–3 sessions of UC-MSCs) ranges from approximately USD 8,000 to 18,000 depending on cell dose, delivery route (IV, intravesical, or combination), and whether maintenance sessions are planned. This includes comprehensive pre-treatment assessment, the MSC product, the procedure itself, and follow-up monitoring. It does not include travel or accommodation. A detailed quote is provided after the initial consultation.

Is stem cell therapy FDA-approved for IC/BPS?

No. MSC therapy for interstitial cystitis is not FDA-approved and is considered investigational everywhere. There is one FDA-approved MSC product (remestemcel-L for pediatric graft-versus-host disease), but that is a completely different indication. All IC/BPS MSC treatments worldwide are off-label or offered under clinical trial or medical tourism frameworks.

How long does it take to see results from MSC therapy for bladder pain?

Anti-inflammatory effects typically begin within 1–2 weeks (reduced urgency, nocturia). Pain relief usually develops over 4–8 weeks as mast cell activity is suppressed. Structural urothelial repair takes 3–6 months. The full clinical benefit is typically assessed at the 6-month mark. Some patients report continued gradual improvement out to 12 months.

Can MSC therapy cure interstitial cystitis?

No published evidence supports a "cure." The goal of MSC therapy in IC/BPS is disease modification — repairing the urothelial barrier, suppressing the neuroinflammatory cycle, and achieving sustained symptom reduction that allows patients to resume normal activities. Many patients in pilot studies achieved clinically meaningful improvement, but symptom-free remission is not the expected outcome and should not be promised.

How does intravesical MSC delivery compare to intravenous?

Intravesical instillation delivers MSCs directly to the bladder urothelium, maximizing local engraftment and GAG layer repair. Intravenous infusion provides systemic immunomodulation and may better address widespread pelvic inflammation and central sensitization. At VELAR, we often combine both routes in a single treatment plan to target both the local urothelial defect and the systemic inflammatory component.

Who is a candidate for MSC therapy for IC/BPS?

Ideal candidates have a confirmed IC/BPS diagnosis (by AUA or ESSIC criteria), have tried and failed at least two tiers of conventional therapy (dietary modification, oral medications, bladder instillations, pelvic floor PT), do not have active urinary tract infection, are not pregnant, and have realistic expectations about the investigational nature of the treatment. Patients with Hunner's lesions, severe bladder wall fibrosis, or reduced bladder capacity under anesthesia may have diminished response and require individualized assessment.

References

  1. Hanno PM, Erickson D, Moldwin R, Faraday MM. Diagnosis and treatment of interstitial cystitis/bladder pain syndrome: AUA guideline amendment. Journal of Urology. 2015;193(5):1545-1553. doi:10.1016/j.juro.2015.01.086 ↩
  2. Clemens JQ, Erickson DR, Varela NP, Lai HH. Diagnosis and treatment of interstitial cystitis/bladder pain syndrome. Journal of Urology. 2022;208(1):34-42. doi:10.1097/JU.0000000000002756 ↩
  3. Birder LA. Pathophysiology of interstitial cystitis. International Journal of Urology. 2019;26(Suppl 1):12-15. doi:10.1111/iju.13985 ↩
  4. Bernardo ME, Fibbe WE. Mesenchymal stromal cells: sensors and switchers of inflammation. Cell Stem Cell. 2013;13(4):392-402. doi:10.1016/j.stem.2013.09.006 ↩
  5. Prockop DJ, Oh JY. Mesenchymal stem/stromal cells (MSCs): role as guardians of inflammation. Molecular Therapy. 2012;20(1):14-20. doi:10.1038/mt.2011.211 ↩
  6. Akiyama Y, Luo Y, Hanno PM, Maeda D, Homma Y. Interstitial cystitis/bladder pain syndrome: the evolving landscape, animal models and future perspectives. International Journal of Urology. 2020;27(6):491-503. doi:10.1111/iju.14236 ↩
  7. Hauser PJ, Dozmorov MG, Bane BL, Slobodov G, Culkin DJ, Hurst RE. Abnormal expression of differentiation-related proteins in urothelial cells from IC/PBS patients. American Journal of Physiology-Renal Physiology. 2008;294(1):F80-F87. doi:10.1152/ajprenal.00306.2007 ↩
  8. Theoharides TC, Kempuraj D, Sant GR. Mast cell involvement in interstitial cystitis: a review of human and experimental evidence. Urology. 2001;57(6 Suppl 1):47-55. doi:10.1016/S0090-4295(01)01128-1 ↩
  9. Lai HH, Gardner V, Ness TJ, Gereau RW. Segmental hyperalgesia to mechanical stimulus in interstitial cystitis/bladder pain syndrome: evidence of central sensitization. Journal of Urology. 2014;191(5):1294-1299. doi:10.1016/j.juro.2013.11.099 ↩
  10. Song M, Lim JE, Lim J, et al. Mesenchymal stem cell therapy alleviates interstitial cystitis by restoring the urothelial barrier. Stem Cells. 2022;40(3):280-293. doi:10.1093/stmcls/sxac001 ↩
  11. Choi BH, Song M, Kim HJ, et al. TSG-6 secreted by mesenchymal stem cells suppresses mast cell activation in interstitial cystitis. Journal of Clinical Investigation. 2020;130(12):6444-6457. doi:10.1172/JCI137445 ↩
  12. Shin JH, Ryu CM, Yu HY, Shin DM, Choo MS. Mesenchymal stem cells reduce nerve growth factor expression and ameliorate bladder pain in a rat model. Scientific Reports. 2019;9:15206. doi:10.1038/s41598-019-51554-y ↩
  13. Jiang W, Xu J. Immune modulation by mesenchymal stem cells. Cell Proliferation. 2020;53(1):e12712. doi:10.1111/cpr.12712 ↩
  14. Kim A, Yu HY, Lim J, et al. Intravesical instillation of umbilical cord-derived mesenchymal stem cells for Hunner-type interstitial cystitis: a pilot study. International Neurourology Journal. 2023;27(2):118-126. doi:10.5213/inj.2346022.011 ↩
  15. Zhang W, Liu Y, Chen J, et al. Autologous bone marrow-derived mesenchymal stem cell therapy for interstitial cystitis/bladder pain syndrome: a pilot study. Stem Cell Research & Therapy. 2021;12:414. doi:10.1186/s13287-021-02504-z ↩
  16. Furuta A, Yamamoto T, Igarashi T, Suzuki Y, Egawa S, Yoshimura N. Mesenchymal stem cell therapy for cystitis in rats. American Journal of Physiology-Renal Physiology. 2017;313(6):F1314-F1323. doi:10.1152/ajprenal.00214.2017 ↩
  17. Baksh D, Yao R, Tuan RS. Comparison of proliferative and multilineage differentiation potential of human mesenchymal stem cells derived from umbilical cord and bone marrow. Stem Cells. 2007;25(6):1384-1392. doi:10.1634/stemcells.2006-0709 ↩
  18. Lalu MM, McIntyre L, Pugliese C, et al. Safety of cell therapy with mesenchymal stromal cells (SafeCell): a systematic review and meta-analysis of clinical trials. PLoS ONE. 2012;7(10):e47559. doi:10.1371/journal.pone.0047559 ↩